One hundred (100) clinical-stage psychedelic and marijuana drug companies are in the clinical stages of research and development of treatments for a wide variety of mental illnesses. Forty (40) of them are based on the use of marijuana THC while the 60 others (see here) are doing so based on the use of one or more of 10 different psychedelic substances (read 10 Psychedelic Substances And The 36 Companies Researching Them). This article updates the stock performances of the 13 constituents in the munKNEE Pure-Play Marijuana and Psychedelic Compounds-Based Drug Stocks Index which have

• market capitalizations of at least US$40M, and
• trade on one or more of the Canadian and/or American stock exchanges.

The Index is divided into:

• • the Pure-Play Marijuana Drug Stocks Index and
  • the Pure-Play Psychedelic Compounds-Based Drug Stocks Index with the latter divided into 2 sub-groups

and is a non-tradable indices which gives each constituent the same importance to provide a comparison of the performance of each with the others and the stated sector as a whole.

You will note that each constituent in the analyses below has 5 areas of additional information that are imperative for any individual considering investing in this sector:

1. The company name is hyperlinked to its website to provide you with a description of the company and an analysis of its stock.
2. The trading symbol is hyperlinked to additional financial data and commentary on the company (where available).
3. The percentage change YTD is hyperlinked to a chart of the company's stock performance.
4. The Chance of Financial Distress percentage is sourced from macroaxis.com (visit the site and type in the stock symbol to obtain detailed financial data on the health of the company).
5. The buy/hold/sell analyst consensus is sourced from stockanalysis.com ((visit the site and type in the stock symbol to obtain a detailed consensus of their recommendations and projections). 

The munKNEE Pure-Play Marijuana Drug Stocks Index

This Index consists of the 4 THC-based drug stocks with market capitalization of at least $40M.  Their performances last week are presented below in descending order:

1. Allied Corp. (ALID): UP +8.2% last week; (DOWN -18.1% YTD)
   • Chance of Financial Distress in next 2 years: +24%
   • Analyst Consensus: No analysts following ALID
2. Zynerba Pharmaceuticals (ZYNE): UP +2.5%; (DOWN -29.9% YTD)
   • Chance of Financial Distress in next 2 years: 6%
   • Analyst Consensus: 12 stock analysts currently rate ZYNE as a BUY and forecast an increase of 280% in the next 12 months.
3. Revive Therapeutics (RVVTF): No Change; (DOWN -33.3% YTD)
   • Chance of Financial Distress in next 2 years: +94%
   • Analyst Consensus: No analysts following RVVTF
4. Corbus Pharmaceuticals (CRBP): DOWN -17.5%; (DOWN -46.8% YTD)
   • Chance of Financial Distress in next 2 years: +89%
   • Analyst Consensus: 10 stock analysts currently rate CRBP as a BUY and forecast an increase of 355% in the next 12 months.

The Index was UP +2.3% this past week but is still DOWN -28.2% YTD and -73.2% from its peak in 2021.

The munKNEE Pure-Play Psychedelic Compounds-Based Drug Stocks Index

This Index consists of 9 psychedelic compound-based drug stocks which are divided into 2 groups based on their market capitalizations: $40M>$399.9M (Group 1) and $400M+ (Group 2).

Group 1

There are 5 constituents in Group 1 and they were UP 11.9%, on average, last week but are still DOWN -37.1% YTD and DOWN -79.2% from their average peaks in 2021. Their performances are presented below in descending order:

1. Field Trip (FTRP): UP +34.3%; (DOWN -42.7% YTD)
   • Chance of Financial Distress in next 2 years: +67%
   • Analyst Consensus: 10 stock analysts currently rate FTRP as a BUY and forecast an increase of 605% in the next 12 months.
2. Seelos (SEEL): UP +4.3%; (DOWN -41.1% YTD)
   • Chance of Financial Distress in next 2 years: +52%
   • Analyst Consensus: 12 stock analysts currently rate SEEL as a BUY and forecast an increase of 809% in the next 12 months.
3. Cybin (CYBN): UP +3.8%; (DOWN -31.7% YTD)
   • Chance of Financial Distress in next 2 years: +62%
   • Analyst Consensus: 14 stock analysts currently rate CYBN as a BUY and forecast an increase of 775% in the next 12 months.
4. Small Pharma (DMTTF): DOWN -5.0%; (DOWN -24.0% YTD)
   • Chance of Financial Distress in next 2 years: +77%
   • Analyst Consensus: No Analysts following DMTTF
5. Numinus (NUMIF): DOWN -5.1%; (DOWN -11.9% YTD)
   • Chance of Financial Distress in next 2 years: +39%
   • Analyst Consensus: No analysts following NUMIF

Group 2

The 4 constituents in Group 2 went UP +7.4%, on average, last week, but are still DOWN -31.8%, on average, YTD, and DOWN -63.4% from their average peaks in 2021. Their performances are presented below in descending order:

1. Mind Medicine (MNMD): UP +20.0; (DOWN -13.0% YTD)
   • Chance of Financial Distress in next 2 years: +62%
   • Analyst Consensus: 8 stock analysts currently rate MNMD as a BUY and forecast an increase of 410% in the next 12 months.
2. Compass Pathways (CMPS): UP +11.5%; (DOWN -38.7% YTD)
   • Chance of Financial Distress in next 2 years: +58%
   • Analyst Consensus: 17 stock analysts currently rate CMPS as a BUY and forecast an increase of 516% in the next 12 months.
3. Atai (ATAI): UP +8.2%; (DOWN -26.0% YTD)
   • Chance of Financial Distress in next 2 years: +52%
   • Analyst Consensus: 19 stock analysts currently rate ATAI as a BUY and forecast an increase of 440% in the next 12 months.
4. GH Resources (GHRS): UP +3.3%; (DOWN -28.3% YTD)
   • Chance of Financial Distress in next 2 years: +39%
   • Analyst Consensus: 10 stock analysts currently rate GHRS as a BUY and forecast an increase of 155% in the next 12 months.

In summary, the munKNEE Pure-Play Marijuana and Psychedelic Compounds-Based Drug Stocks Index went UP +7.3% last week but is still DOWN -32.0% YTD and DOWN -66.6% from its peak in 2021.